<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195243</url>
  </required_header>
  <id_info>
    <org_study_id>CUCS-INTEC-MV-HADES-001</org_study_id>
    <nct_id>NCT04195243</nct_id>
  </id_info>
  <brief_title>Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Acute Effect of Dapagliflozin vs Empagliflozin Administration on Flow Mediated Dilation in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitario de Ciencias de la Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Universitario de Ciencias de la Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a considered one of the main global health challenges; the
      vascular endothelium plays an important role in vascular dysfunction in DM; Hyperglycemia
      induced by it is recognized as the main factor for the development of vascular complications
      of the disease, secondary to a reduction in nitric oxide production; &quot;flow-mediated dilation&quot;
      is the most commonly used technique for the evaluation of endothelial function, being the
      non-invasive method most widely used. It has been reported that with the use of SGLT2
      inhibitors the development of cardiovascular complications in patients with T2DM is a
      decrease, as well the arterial stiffness, endothelial dysfunction and increasing on the shear
      stress and blood viscosity; and experimentally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study, is to evaluate the acute effect of the administration of
      dapagliflozin in comparison with the administration of empagliflozin on endothelial
      disfunction in individuals with T2DM; we will conduct a double-blind, randomized,
      placebo-controlled, trial with 3 groups, each group of 24 male and female patients, between
      40-65 years of age with T2DM, without hypertension, treated with insulins or thiazide
      diuretics. Randomization will determine who will receive the intervention during 7-days trial
      (Empagliflozin 25 mg 1 time daily 5 minutes or Dapagliflozin 10 mg before the first bite of
      each meal or approved placebo capsules), the patients will also continue with their usual
      treatment. The clinical findings and laboratory test and laboratory test include a metabolic
      profile and biosafety, baseline and at 7 days. Body weight, body fat, body mass index (BMI)
      and blood pressure will be determined during the initial and final visit, likewise,
      hemodynamics parameters of endothelial disfunction by flow mediate dilation with a
      high-resolution UNEX EF38G® ultrasound. Adverse events to treatment will be documented.
      Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. A p &lt;0.05 will be
      considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Dilation</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline Flow mediated dilation at 7 days. Using a high-resolution UNEX EF38G ultrasound®, in a room at 22°C, with the patient lying supine, and the right arm extended</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Glucose Oxidase / Peroxidase kit; in an automated clinical chemistry analysis equipment brand XL-100Erba</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Glucose Oxidase / Peroxidase kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Glycerol phosphate Oxidase / Peroxidase kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention, using the BioSystems® Direct / Detergent HDL kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention using the BioSystems® Cholesterol Oxidase / Peroxidase kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention the BioSystems® kit Modified Jaffe's no deproteinization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>7 days</time_frame>
    <description>Before and after intervention using an OMRON calibrated electronic digital sphygmomanometer model HEM 907 XL will be used. The patient will remain seated in a chair resting his back on the backrest, with a minimum rest of 5 minutes, The average of 3 measurements such as BP will be taken</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin Pill</intervention_name>
    <description>The patient will take one pill, every 24 hr, during 7 days</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
    <other_name>Dapagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Pill</intervention_name>
    <description>The patient will take one pill, every 24 hr, during 7 days</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
    <other_name>Empagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>The patient will take one pill, every 24 hr, during 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T2DM

          -  HbA1c &gt; 7 y &lt; 10

          -  BMI 25 - 34.9 kg/m2

          -  Signature of consent under information

        Exclusion Criteria:

          -  Hypertension

          -  Treated with insulin and / or loop diuretics and thiazides

          -  T1DM

          -  Hypotension

          -  With any autoimmune disease

          -  Liver disease

          -  Women who do not have a safe method of contraception

          -  Women who are taking oral contraceptives or under treatment with hormone replacement
             therapy

          -  Woman pregnant or breastfeeding

          -  Untreated thyroid disease

          -  Patients with a cardiovascular disease that contraindicates the use of this
             pharmacological class

          -  Glomerular filtration rate &lt;60ml/min (Cockcroft-Gault)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Grover Paez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Grover Paez, PhD</last_name>
    <phone>(33) 10585200</phone>
    <phone_ext>34215</phone_ext>
    <email>fgroverp@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Grover Paez, PhD</last_name>
      <phone>(33) 10585200</phone>
      <phone_ext>34215</phone_ext>
      <email>fgroverp@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Grover Paez, PhD</last_name>
      <phone>(33) 10585200</phone>
      <phone_ext>34215</phone_ext>
      <email>rballezaa@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Universitario de Ciencias de la Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Grover Paez</investigator_full_name>
    <investigator_title>Investigador Principal</investigator_title>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>FMD</keyword>
  <keyword>T2DM</keyword>
  <keyword>Endothelial disfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

